Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Stüve, O; Cravens, PD; Frohman, EM; Phillips, JT; Remington, GM; von Geldern, G; Cepok, S; Singh, MP; Cohen Tervaert, JW; De Baets, M; MacManus, D; Miller, DH; Radü, EW; Cameron, EM; Monson, NL; Zhang, S; Kim, R; Hemmer, B; Racke, MK 
Titel:
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. 
Abstract:
OBJECTIVE: Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple sclerosis (MS). A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard to gadolinium enhancing lesions on MRI 3 months after discontinuation of therapy. The objective of this study was to assess clinical MS disease activity, surrogate disease markers on MRI, immunologic...    »
 
Zeitschriftentitel:
Neurology 
Jahr:
2009 
Band / Volume:
72 
Heft / Issue:
Seitenangaben Beitrag:
396-401 
Sprache:
eng 
Print-ISSN:
0028-3878 
TUM Einrichtung:
Neurologische Klinik und Poliklinik